About Diarect
Diarect is a Healthcare company based in Baden-baden (Germany) founded in 1998 by Bodo Liedvogel and Heinz Haubruck, and was acquired by BBI Group in June 2020. Recombinant and native antigens. The company has 289 employees. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified. Its legal entity is BBI SOLUTIONS OEM LIMITED.
Company details
Diarect specializes in the development and production of recombinant and native antigens that are used in the development of immunoassays. The company manufactures a host of allergens (found in food, grasses and trees), a large collection of autoimmune disease antigens (including, SARD, Mixed Connective Tissue Disease, SLE, Sjøgrens Syndrome, Systemic Sclerosis CREST Syndrome, Polymyositis Dermatomyositis, Autoimmune Thyroid Diseases, Celiac Disease, Autoimmune Hepatitis, Primary Biliary Cirrhosis, ANCA-Associated Diseases, Antiphospholipid Syndrome Thromboembolic Syndrome, Anti-GBM Disease, Diabetes Mellitus, Pernicious Anemia, Crohns Disease), and infectious disease antigens (including Anaplasmosis, Babesiosis, Borreliosis Lyme Disease Relapsing Fever, Candidiasis, Erythema infectiosum, Scarlet Fever, Yersiniosis). The company is also the European distributor of SurModics protein stabilization reagents and blockers and BioFX substrates.
- Headquarters Baden-baden, Germany
- Employees 289
- Founders Bodo Liedvogel, Heinz Haubruck
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website diarect.com
- Social LinkedIn
- Acquired by BBI Group (Jun 2020)
- Legal Name Bbi Solutions Oem Limited
- Latest Funding Round$700.09K (USD), Grant
Jul 2016
- InvestorsEuropean Union
& 1 more
- Employee Count289
- Acquired byBBI Group
(Jun 2020)
Funding Insights of Diarect
- Total Rounds 1
- Last Round Grant — $700,085
- First Round $700,085
(Jul 2016)
- Investors Count 1
All 1 funding rounds of Diarect with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2016 | $700,085 | Grant | – | – |
2 investors in total: 2 institutional.
Investors in Diarect
Diarect has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include European Union and BBI Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Instruments and reagents are supplied for diagnostic and healthcare sectors. | 1986 | the-bbigroup.com | Cardiff, United Kingdom |
Investor details for Diarect
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Diarect
2 people are tracked at Diarect (2 in leadership); the tracked headcount is 289.
| Name | Role | Group |
|---|---|---|
Bodo Liedvogel | Co-Founder | Leadership |
Heinz Haubruck | Co-Founder | Leadership |
Complete people profiles for Diarect
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Diarect
3 dated milestones of Diarect across 22 years, from founding to its latest funding, stage changes and deals.
- Founded Diarect is founded.
- Funding First funding round of $700K.
- Exit Acquired by BBI Group.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Diarect
Complete news archive for Diarect
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Diarect
Diarect was founded in 1998 and raised its 1st funding round 18 years after it was founded.
Diarect is headquartered in Baden-baden, Germany. It is registered at Baden-baden, Baden-wurttemberg, Germany.
Diarect has 289 employees.
Diarect specializes in the development and production of recombinant and native antigens that are used in the development of immunoassays. The company manufactures a host of allergens (found in food, grasses and trees), a large collection of autoimmune disease antigens (including, SARD, Mixed Connective Tissue Disease, SLE, Sjøgrens Syndrome, Systemic Sclerosis CREST Syndrome, Polymyositis Dermatomyositis, Autoimmune Thyroid Diseases, Celiac Disease, Autoimmune Hepatitis, Primary Biliary Cirrhosis, ANCA-Associated Diseases, Antiphospholipid Syndrome Thromboembolic Syndrome, Anti-GBM Disease, Diabetes Mellitus, Pernicious Anemia, Crohns Disease), and infectious disease antigens (including Anaplasmosis, Babesiosis, Borreliosis Lyme Disease Relapsing Fever, Candidiasis, Erythema infectiosum, Scarlet Fever, Yersiniosis). The company is also the European distributor of SurModics protein stabilization reagents and blockers and BioFX substrates.
Diarect has 2 investors. Key investors include European Union, and BBI Group.
Diarect operates through Bbi Solutions Oem Limited.
Yes. Diarect was acquired by BBI Group in June 2020.